fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Terconazole

All products: general benefit

Taro-Terconazole · DIN 02247651 · 0.4% · Vag Cr

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Taro-Terconazole · DIN 02247651 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2005-06-13 Health Canada: Marketed since 2004-09-21 · brand TARO-TERCONAZOLE · ATC G01AG02 TERCONAZOLE · form Cream · route Vaginal · ingredients TERCONAZOLE 0.4 % · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Taro-Terconazole: Formulary list price $0.64 per unit (the source does not state the unit; exact figure $0.6354). What the ministry pays, not the patient.

Ministry pays: $0.6354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247651)

Source record
DIN 02247651: Taro-Terconazole Raw flags: sec3=Y Item: 840408042; group id 825; item number 2010; lccId None; manufacturer id TAR Source form: Vag Cr; strength: 0.4% Recorded listing: General benefit Source prices (unrounded): $0.6354; ministry $0.6354 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247651 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71914
Interchangeable products
Terazol 7 · DIN 00894729 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (G01A): coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, not a benefit
  • Nystatin (Mycostatin): general benefit, not a benefit
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

FLUCONAZOLE

· 9 products · Limited Use, codes 235 · strengths: 150mg · Cap

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TARO-TERCONAZOLE (terconazole) Vaginal Cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). The diagnosis of monilial infection should be confirmed by TARO-TERCONAZOLE Vaginal Cream 0.4% Product Monograph Page 2 of 21 microscopic examination of a KOH smear and/or by culture. TARO-TERCONAZOLE vaginal cream may be used in pregnant patients during the second and third trimester if the physician considers it essential to the welfare of the patient (see PRECAUTIONS, Use During Pregnancy). The therapeutic effect of TARO-TERCONAZOLE vaginal cream is not affected by oral contraceptive usage, menstruation or previous monilial infection. https://pdf.hres.ca/dpd_pm/00064148.PDF PM date: December 23, 2021 Source product: TARO-TERCONAZOLE; DIN 02247651; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.